AC
KURA icon

Annandale Capital’s Kura Oncology KURA Stock Holding History

Annandale Capital’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$106K – 140
2023
Q2 		$106K Hold
10,000
– – 0.03% 130
2023
Q1 		$122K Hold
10,000
– – 0.04% 121
2022
Q4 		$124K Hold
10,000
– – 0.04% 120
2022
Q3 		$137K Buy
+10,000
New +$154K 0.05% 122

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Annandale Capital's KURA Position: Q3 2023 in Review

Annandale Capital sold out of Kura Oncology (KURA) in Q3 2023, closing a stake of 10,000 shares — an estimated $106K sold.

Annandale Capital first reported a position in KURA in Q3 2022 and held it in 4 quarters. The position peaked at $137K in Q3 2022. 133 funds tracked by Wall St. Rank hold KURA as of Q3 2023.

  • Annandale Capital reported no remaining Kura Oncology position as of Q3 2023 after selling out during the quarter.
  • Annandale Capital sold 10,000 Kura Oncology shares in Q3 2023, an estimated $106K.
  • Annandale Capital first reported a position in Kura Oncology in Q3 2022 and held it in 4 quarters.
  • Annandale Capital's Kura Oncology position peaked at $137K in Q3 2022.
  • 133 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2023.

Based on Annandale Capital's 13F filing for Q3 2023, filed 15 Nov 2023.